Method lf preparing hexahydro-gamma-carbolines or their salts

专利摘要:
5-Phenyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indoles, which are substituted in position 2, and their salts of formula I, the symbols of which are explained in Claim 1, are described. These compounds and their salts are therapeutically active and can be used as medicaments for controlling schizophrenic symptoms. The pharmaceutical compositions are also described. The new compounds and their salts can be obtained by processes which are especially distinguished from others by the formation of the substituent in position 2; the latter is obtained by processes which each contain a reduction stage, from compounds which already have the pyridoindole system. <IMAGE>
公开号:SU841589A3
申请号:SU792763595
申请日:1979-05-18
公开日:1981-06-23
发明作者:МакКован Велч Виллард (младший)
申请人:Пфайзер Инк (Фирма)；
IPC主号:

专利说明:

The invention relates to the preparation of new hexahydro-3 carboline derivatives, which can be used in medicine. The reaction of carboxylic acids with amines in the presence of carbodiimide fl. Is known. The purpose of the invention is the development, on the basis of a known method, of a method for the preparation of new compounds possessing valuable pharmacological properties. This goal is achieved by the method of obtaining hexagid- | -carboline of the general formula // OH is the same or different where X and and are hydrogen or fluorine ;;; hydrogen, fluorine or. methoxy group; 3 or 4. These compounds are obtained by reacting 4a, 9c-trans-hexahydro-carboline in the general form. Where X and Y have the above values, with a carboxylic acid of the general formula C - (SI,} -COOH where Z and n have the above values or its acid halide in an organic solvent medium. Examples of solvents that can be used for this purpose are dichloromethane, chloroform, tetrahydrofuran, ethyl ether and benzene. The process is carried out at a temperature of 0 C. At this temperature, the reaction is usually completed within a few hour . The product was dissolved vschel, e.g., filtration to remove insoluble matter and evaporation of the solvent. The resulting product is generally pure enough for use at the next stage.
The intermediate is then reacted with lithium aluminum hydride in an inert solvent such as ethyl ether or tetrahydrofuran, and the product is isolated and purified, for example, on a chromatographic silica gel column.
The resulting bases can form acid addition salts. Such basic compounds are converted to acid addition salts by reacting bases with an acid in either an aqueous or non-aqueous medium. Similarly, treating an acid addition salt with an equivalent amount of an aqueous base solution, for example, alkali metal hydroxides, alkali metal carbonates and alkali metal bicarbonates, or an equivalent amount of metal cations that form an insoluble precipitate with acid anions, results in a free base form. The bases thus reduced can be converted back to the same or different acid addition salts.
Examples of acids that give family-acceptable anions are hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, sulfurous, phosphorus, acetic lactic, citric, tartaric, succinic, maleic and gluconic acid.
The proposed compounds can be easily adapted for therapeutic use as a Tori tranquilis for mammals. Investigators are characterized in that they remove such manifestations of human schizophrenia. Like hallucinations, hostility, suspicion, emotional or social breakdowns, anxiety, excitement and intensity.
Carbolines and their pharmaceutically acceptable salts, which are useful tranquilizers, can be taken either as independent therapeutic agents, or as mixtures of therapeutic agents. They can be administered separately, usually taken with a pharmaceutical carrier, selected based on the usual method of administration. and routine pharmaceutical practice. For example, they can be taken orally in the form of tablets or capsules containing such additives as starch, milk sugar or certain types of clays, etc. In addition, it is possible to use in the form of elixirs or. suspensions for oral administration when the active ingredient is combined with emulsifying or suspending agents. They can also be administered parenterally by injection, and for this they or the corresponding derivatives can be obtained in the form of sterile iodine solutions. An appropriate buffer should be added to such aqueous solutions, if necessary, and they should contain other solutions, such as physiological or glucose, to give the desired isotonicity.
All compounds of formula 1 contain at least two asymmetric centers formed during the reduction of the double bond 4a, 9b to trans-condensed systems.
The resulting novel compounds include both racemates and individual enantirmers.
Example 1. dl-trans-2, (4-hydroxy-4-phenylbutyl) -5-phenyl-2,3, 4, 4a, 5, 9c-hexahydro-1H-pyrido- (4, 3-in indole.
BUT). To the suspension obtained by mixing 865 mg (4.20 mmol) of dicyclohexylcarbodiimide and 748 mg (4.20 mmol) of 3-benzoylprop-pyrnic acid in 30, l of dichloromethane were added with 1.0 IZ (4.0 mmol) of SZE-trans 5-phenyl-2, 3,4,4a, 5,9v-hexahydro-1H-pyrido (4.3, in -) - indole in 10 ml of the same solvent. The mixture was stirred and warmed to room temperature over 2 hours. After cooling again, the reaction mixture is filtered, washed with dichloromethane and the resulting filtrates are evaporated, resulting in a residue of dl-trans-2- (benzoyl) propionyl} -5-phenyl-2,3, 4,4a, 5,9v-hexahydro -1-pyrido (4,3-b) indole, which is used in the next step without further purification.
at). The residue obtained from the previous test was dissolved in 50 ml of tetrahydrofuran and heated at reflux temperature. A filtered solution of lithium aluminum hydride in the same solvent is added until gas evolution (molar excess) occurs and the resulting mixture is transferred at reflux temperature for 5-10 minutes, after which the mixture is cooled. Powdered porous anhydrous sodium sulfate (17 g) was added, and then 0.5 ml of water was added. The mixture was stirred at room temperature for 30 minutes, filtered, and the resulting filtrate was evaporated to dryness in vacuo. The residue is placed on a chromatographic column containing 80 g of silica gel and eluted with a mixture of ethyl acetate and methanol (4: 1 volume; resulting in a free base of the hexa hydro-T-carboline compound after solvent is evaporated. The free base is converted to the hydrochloride salt dissolving in ether, by adding a saturated solution of anhydrous hydrogen chloride in ether until the precipitate is formed, is filtered off and dried, yielding 1.04 g of product, melting point 222-224 .
Infrared spectrum (kVg) M: 3.97; 3, (broad); 6 ,,, 88, 7,; 96; 8.18} 8.15; 9.82j Mass spectrum, M / e: 398, 292, 263, 249.220, 207.192. (100%) ; UV (methanol) .LKa, 245 / e 0.653x lOj270 / e 0.914K1C4
Example 2. Using the appropriate starting materials, each time selected from free bases, and the corresponding 3-benzoylpropionic acid, the following d1 trans compounds are prepared according to the procedure of Example 1. All products are isolated in the form of hydrochloric acid salts, unless otherwise indicated.
Table 1 shows the composition and characteristics of the properties of the proposed compounds. 25
Table 1
ra i
Output,%
Temperature
melting
3 220-223
18 39
F H C 239-245 N F
H SN.O 3 Amorphous-solid (a).,
F SNZO 3 45-48,5 (VG
31 (a) -mass spectrum, M / e: 428, 411 263 (100%), 220, 206,204j IR spectrum (KBG) M: 2.98; 3.42; 4.07 (wide); 6.20; 6.27; 6.70; 6.98; 8.04; 8.54; 9.77; 12.05. (in the 1; melting point and the yield is indicated for the free base. Example 3. Starting from the corresponding d1-trans-hexahydro-1H-pyri to- (4,3-c) indoles i selected from the corresponding substituted 3-benzylpropionic or 4- benzoyl butyric acid, similarly to example 1, the following compounds are obtained, the composition of which is given in Table 2. Table 2 Composition of d1-trans-compounds .. 3 F Para-fluor Meta-fluor 3 F Para-fluor Ortho-methoxy
Continued table. 2
Composition -d1-trans-compounds
..l.r
thirty
35 Example 4. dl-trans-8-fluorop-5-phapa fluorophenium acetate) -2- 4-hydroxy-4- (parafluorophenyl butyl-2,3,4,4a, 5, 9b-hexahydro-1H-pyrido-C4 ,) indole. Five grams of d1-trans-8-fluoro-5- (para-fluorophenyl) -2-4-hydroxy-4 (para-fluorophenyl) butyl -2,3,4,4a, 5.9v-hexahydro-1H- hydrochloride pyrido (4, 3-b) indole in 75 ml of water is treated with 3 ml of water containing 1.0 g of sodium hydroxide, and the liberated free base is extracted with 150 ml of diethyl ether. The ether layer was separated, dried over magnesium sulfate, and treated with -1 ml of glacial acetic acid. The organic solvent and excess acetic acid were removed under a reduced pressure, and the resulting residue was triturated with hexane and filtered.

权利要求:
Claims (2)
[1]
Other addition salts are prepared in a similar manner, especially those that are pharmaceutically acceptable. Claims 1. A method for producing hexagidr -carbolines of the general formula (CH,) - CH - {3 OH where X and Y are the same or diffused and are fluorine hydrogen; Z is hydrogen, fluorine, or me; n 3 or 4; or their salts, characterized in that 4a, 9b is trans-hexahide -carboline of the general form. Type X. G I 1 t
where X and Y have the above meanings, are reacted with a carboxylic acid of the general formula
ABOUT
I /
c- (cn-.} -soon, where Z and p have the above-mentioned values, or its halogenohydride in the presence of dicyclohexylcarbodiimide in the medium of an organic solvent while cooling to. followed by reduction of the compound of the general formula if), where X, y, Z, and p are as defined above, with lithium aluminum hydride in an inert organic solvent and isolating the desired product in free form or as a salt.
[2]
2. A method according to claim 1, characterized in that ethyl, ether or tetrahydrofuran is used as an inert organic solvent for reduction. Sources of information taken into account in the examination 1. BülerK. and Pearson D. Organic syntheses. 1973, part 2, p. 384.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP2716146B2|1998-02-18|Condensed indole derivative and method for producing the same

---

US4404206A|1983-09-13|Substituted iminoacid derivatives, process for preparing them and their use as enzyme inhibitors

---

US5354760A|1994-10-11|Crystalline Tiagabine monohydrate, its preparation and use

---

JP3122792B2|2001-01-09|New active compounds

---

SU841589A3|1981-06-23|Method lf preparing hexahydro-gamma-carbolines or their salts

---

CS221807B2|1983-04-29|Method of making the trans-2-substituted-5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido/4,3b/indole

---

US4585769A|1986-04-29|Benzenesulfonyl-lactams and their use as active substances of pharmaceutical compositions

---

EP0499995B1|1997-01-02|Piperidine derivatives

---

EP0008249B1|1981-08-26|Fluorene and fluoranthene derivatives, process for their preparation and their therapeutic application

---

SE461653B|1990-03-12|PROCEDURES FOR THE PREPARATION OF AMINOEBURNAND DERIVATIVES

---

JP2609410B2|1997-05-14|Production of | -2- | -7- | octahydro-2H-pyrido [1,2-a] pyrazine

---

JP2753146B2|1998-05-18|Preparation of bis-azabicyclic anxiolytics and intermediates

---

US4052404A|1977-10-04|Indolo |quinolizines

---

JPH0670032B2|1994-09-07|Aminopyrrolidine derivative, its ester and its salt

---

EP0812838A1|1997-12-17|Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor

---

SU564813A3|1977-07-05|Method for obtaining derivatives of indoloquinolysine or their salts

---

US4329350A|1982-05-11|1,1-Disubstituted octahydro-indolo[2,3-a]quinolizines, process for the preparation thereof and compositions containing same

---

JPH0764844B2|1995-07-12|Pyridazinopyrroloisoquinoline derivative

---

JPH0635458B2|1994-05-11|Pyridonecarboxylic acid derivatives, their esters and their salts

---

US2778829A|1957-01-22|New 5:6-dihydro-benzo | cinnoline derivatives and a process for their preparation

---

IL38550A|1974-11-29|Acyl derivatives of digoxin and process for the production thereof

---

JPH05213754A|1993-08-24|Antiulcer agent

---

GB2124214A|1984-02-15|Apovincaminic acid derivatives

---

DE3545206A1|1987-06-25|SUBSTITUTED 4-FLUOR-ISOINDOLINE, METHOD FOR THE PRODUCTION AND USE THEREOF AND PREPARATIONS CONTAINING THESE COMPOUNDS

---

KR810000801B1|1981-07-08|Process for production of 2-tetrahydrofurfuryl-6,7 benzomorphanes

同族专利:

---

公开号 | 公开日

---

DK226678A|1978-11-24|

---

AU499618B1|1979-04-26|

---

JPS53144600A|1978-12-15|

---

FI781612A|1978-11-24|

---

GR69985B|1982-07-22|

---

DE2822465A1|1978-11-30|

---

BE867249A|1978-11-20|

---

YU221882A|1983-01-21|

---

NO151862B|1985-03-11|

---

SE448459B|1987-02-23|

---

GB1586655A|1981-03-25|

---

DE2822465C2|1986-08-28|

---

IT7823673D0|1978-05-22|

---

DD145537A5|1980-12-17|

---

FI63402B|1983-02-28|

---

EG13590A|1982-03-31|

---

NO151862C|1985-06-19|

---

PL206903A1|1979-10-22|

---

SE7803625L|1978-11-24|

---

YU40796B|1986-06-30|

---

NO831790L|1978-11-24|

---

LU79684A1|1979-12-06|

---

IE46975B1|1983-11-16|

---

HU185009B|1984-11-28|

---

SE441448B|1985-10-07|

---

PL114541B1|1981-02-28|

---

SU843749A3|1981-06-30|

---

HU188802B|1986-05-28|

---

YU91478A|1983-01-21|

---

IT1096307B|1985-08-26|

---

PL114547B1|1981-02-28|

---

NZ187333A|1984-05-31|

---

AT368995B|1982-11-25|

---

NO150204C|1984-09-05|

---

SU818484A3|1981-03-30|

---

PH13756A|1980-09-17|

---

IL54755A|1981-02-27|

---

CS207612B2|1981-08-31|

---

PL116944B1|1981-07-31|

---

FR2392023B1|1980-11-07|

---

ATA369678A|1982-04-15|

---

IL54755D0|1978-07-31|

---

HU187782B|1986-02-28|

---

CA1094071A|1981-01-20|

---

ZA782918B|1979-06-27|

---

IE781013L|1978-11-23|

---

PT68058B|1979-10-24|

---

AR221721A1|1981-03-13|

---

FR2392023A1|1978-12-22|

---

SE8305917L|1983-10-27|

---

NO781770L|1978-11-24|

---

YU221682A|1983-01-21|

---

DD146186A5|1981-01-28|

---

PL117107B1|1981-07-31|

---

NO150204B|1984-05-28|

---

AR217688A1|1980-04-15|

---

PT68058A|1978-06-01|

---

DD138321A5|1979-10-24|

---

SU873883A3|1981-10-15|

---

DD145536A5|1980-12-17|

---

JPS5711912B2|1982-03-08|

---

FI63402C|1983-06-10|

---

NL7804210A|1978-11-27|

---

CH634321A5|1983-01-31|

---

SE8305917D0|1983-10-27|

---

YU221782A|1983-01-21|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

AR205452A1|1973-12-06|1976-05-07|Endo Lab|METHOD TO PREPARE NEW TRANS-2, 3, 4, 4A, 5, 9B-HEXAHYDRO-5-PHENYL-1H-PYRID INDOLES|

---

JPS50126699A|1974-03-20|1975-10-04|

---

US4001263A|1974-04-01|1977-01-04|Pfizer Inc.|5-Aryl-1,2,3,4-tetrahydro-γ-carbolines|US4224329A|1979-01-23|1980-09-23|Pfizer Inc.|2-Substituted-trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indoles|

---

US4451655A|1982-05-17|1984-05-29|Pfizer Inc.|Process for preparing carboline derivatives and compounds used in their preparation|

---

RU2106864C1|1995-10-23|1998-03-20|Николай Серафимович Зефиров|New approach to treatment of alzheimer's disease|

---

US6974825B1|1996-12-20|2005-12-13|Astrazeneca Canada Inc.|Compounds with analgesic effect|

---

SE9604786D0|1996-12-20|1996-12-20|Astra Pharma Inc|New compounds|

---

SE9904675D0|1999-12-20|1999-12-20|Astra Pharma Inc|Novel compounds|

---

SE0101773D0|2001-05-18|2001-05-18|Astrazeneca Ab|Novel compounds|

---

SE0101769D0|2001-05-18|2001-05-18|Astrazeneca Ab|Novel compounds|

---

SE0101770D0|2001-05-18|2001-05-18|Astrazeneca Ab|Novel compounds|

---

SE0101771D0|2001-05-18|2001-05-18|Astrazeneca Ab|Novel compounds|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US79939277A| true| 1977-05-23|1977-05-23|

---